Urological Devices | China | 2015 | Market Analysis
While domestic manufacturers remain entrenched in a number of segments in the Chinese urological device market, rising procedure volumes and the growing uptake of minimally invasive treatments will result in more market opportunities for MNCs.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in China across a 10-year period.
TURP will remain a popular procedure to treat BPH in China.
What percentage of procedures will use a monopolar electrode? What percentage will use a bipolar electrode?
How will the market growth of PVP and holmium lasers be impacted?
Flexible endoscopy is currently underpenetrated in China but an increasing number of urologists will gain experience in its use over the forecast period.
How will procedures like PCNL or ESWL, which do not use endoscopes, be impacted?
How many flexible cystoscopes and flexible ureteroscopes will be sold in the country?
There are numerous domestic Chinese manufacturers of urological devices that hold a significant portion of the market share.
In which device markets do domestic manufacturers dominate?
What are some strategies that MNCs can employ to gain market share?
